ABBV Hits A High Note, AGN Opens Wallet, TEVA’s HALO Does An Encore

Today’s Daily Dose brings you news about Karyopharm’s BOSTON study; Synergy Pharma’s upcoming regulatory catalyst related to Trulance; FDA panel review of ABP 215, a biosimilar candidate to Roche’s Avastin; TEVA’s HALO study and AbbVie’s SELECT-NEXT study. Read on… AbbVie’s (ABBV) phase III clinical trial of Upadacitinib in patients with moderate to severe rheumatoid arthritis …